PEA in Functional Dyspepsia

Last updated: June 28, 2024
Sponsor: Universitaire Ziekenhuizen KU Leuven
Overall Status: Active - Recruiting

Phase

N/A

Condition

Bowel Dysfunction

Heartburn (Pediatric)

Stomach Discomfort

Treatment

Palmitoylethanolamide

Clinical Study ID

NCT05877781
S65406
  • Ages 18-70
  • All Genders

Study Summary

The goal of this placebo controlled randomized double blind interventional study is to assess the effect of palmitoylethanolamide supplementation in patients with functional dyspepsia The main questions it aims to answer are:

  • The efficacy of PEA on functional dyspepsia symptoms measured using the LPDS questionnaire

  • The effect of PEA on duodenal mucosal permeability.

Participants will receive an 8-week during treatment with PEA 3x400 mg per day or placebo 3 times per day.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with functional dyspepsia as diagnosed by the Rome IV criteria.

  • Subjects must provide witnessed written informed consent prior to any studyprocedures being performed.

  • Subjects aged 18-70 years old.

  • Male or female subjects.

  • Subjects who are capable to understand the study and the questionnaires, and tocomply with the study requirements.

  • Women of child-bearing potential agree to apply a highly effective method of birthcontrol during the entire duration of the trial. Highly effective birth control isdefined as those which result in a low failure rate (i.e., less than 1% per year)when used constantly and correctly such as implants, injectables, combined oralcontraceptive method, or some intrauterine devices (IUDs), sexual abstinence, orvasectomized partner. Women of non-childbearing potential may be included ifsurgically sterile (tubal ligation or hysterectomy) or postmenopausal with at least 2 year without spontaneous menses.

Exclusion

Exclusion Criteria:

  • Presence of a history of gastrointestinal surgery other than appendectomy andcholecystectomy.

  • Organic gastro-intestinal disease

  • Major psychiatric disorder such as major depression

  • Presence of coeliac disease, lupus, scleroderma and other systemic auto-immunedisease.

  • Patients with eosinophilic esophagitis

  • Presence of diabetes mellitus

  • Active H. Pylori infection or < 6 months after eradication

  • Predominant IBS (based on the Rome IV questionnaire)

  • Predominant GERD (based on the Rome IV questionnaire)

  • Patients taking prohibited medication

  • Females who are pregnant or lactating

  • Patients not capable to understand or be compliant with the study.

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: Palmitoylethanolamide
Phase:
Study Start date:
November 29, 2021
Estimated Completion Date:
March 01, 2025

Connect with a study center

  • KU Leuven

    Leuven, Vlaams-Brabant 3000
    Belgium

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.